Interview with the CEO and the EVP and CFO: Abivax SA (OTCMK

Our lead drug candidate, obefazimod, has generated promising results in Phase IIa and Phase IIb clinical trials for the treatment of ulcerative colitis, a chronic inflammatory bowel disease, and in a Phase IIa clinical trial in rheumatoid arthritis.

Related Keywords

Austria , Netherlands , France , Lower Austria , Niederörreich , French , Austrian , States Eli Lilly , Sanofi Pasteur , Baxter Bioscience , Hartmutj Ehrlich , Institute Of Nancy , Indiana University , Germany Max Planck Foundation , French Business School , University Of Nancy , Novartis , Adjunct Professor Of The Danube University Krems , Chief Executive Officer , United States , Eli Lilly , Central Laboratory , Dutch Red Cross , Max Planck Foundation , Austrian President , Austrian Minister , Danube University Krems , Chief Financial Officer , Board Secretary , Commercial Operations , Price Waterhouse Coopers , Commercial Institute , French Business , Professional Certificate ,